Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease ( PSC‐IBD ): A matched analysis from the Paediatric PSC Consortium
Alimentary Pharmacology & Therapeutics · 2024-05 · 59 (10) · 1236-1247
DOI: 10.1111/apt.17936 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 10.03.2024. Verfasst von Amanda Ricciuto und 38 weiteren Autor:innen. Beteiligte Einrichtung: The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Vancomycin, Cholangitis, Sclerosing, Anti-Bacterial Agents, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: PSC Partners Seeking a Cure.
Abstract (Originalsprache)
Background
Data on oral vancomycin for primary sclerosing cholangitis (PSC)‐associated inflammatory bowel disease (IBD) are limited.
Aims
Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity.
Methods
In this retrospective multi‐centre cohort study, we matched vancomycin‐treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE.
Results
113 PSC‐IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin‐treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97–6.31; adjusted OR [aOR] 5.24, 95% CI 2.68–10.22). Benefit was maintained in sensitivity analyses restricted to non‐transplanted patients and those with baseline moderate–severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002–7.62; N = 101 with data), and with lower CRP ( p = 0.03) and higher haemoglobin and albumin (both p < 0.01).
Conclusion
Vancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
- Max Rady College of Medicine, Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.
- Duke University Medical Center, Durham, North Carolina, USA.
- Dana-Dwek Children's Hospital, Tel-Aviv Medical Center, Tel-Aviv University, Tel Aviv, Israel.
- CHU de Lille, Lille, France.
ORCID-Profile: Amanda Ricciuto, Aldo Montano-Loza
Förderung
- PSC Partners Seeking a Cure
Zitieren
APA
Ricciuto, A., Liu, K., El-Matary, W., Amin, M., Amir, A. Z., Aumar, M., Auth, M., Di Guglielmo, M. D., Druve Tavares Fagundes, E., Rodrigues Ferreira, A., Furuya, K. N., Gupta, N., Guthery, S., Horslen, S. P., Jensen, K., Kamath, B. M., Kerkar, N., Koot, B. G. P., Laborda, T. J., …, & Pediatric PSC Consortium (2024). Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease ( PSC‐IBD ): A matched analysis from the Paediatric PSC Consortium. Alimentary Pharmacology & Therapeutics, 59(10), 1236-1247. https://doi.org/10.1111/apt.17936
Vancouver
Ricciuto A, Liu K, El-Matary W, Amin M, Amir AZ, Aumar M, et al. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease ( PSC‐IBD ): A matched analysis from the Paediatric PSC Consortium. Alimentary Pharmacology & Therapeutics. 2024;59(10):1236-1247. doi:10.1111/apt.17936
BibTeX
@article{Ricciuto2024,
author = {Ricciuto, Amanda and Liu, Kuan and El-Matary, Wael and Amin, Mansi and Amir, Achiya Z and Aumar, Madeleine and Auth, Marcus and Di Guglielmo, Matthew D and Druve Tavares Fagundes, Eleonora and Rodrigues Ferreira, Alexandre and Furuya, Katryn N and Gupta, Nitika and Guthery, Stephen and Horslen, Simon P and Jensen, Kyle and Kamath, Binita M and Kerkar, Nanda and Koot, B G P and Laborda, Trevor J and Lee, Christine K and Loomes, Kathleen M and Mack, Cara and Martinez, Mercedes and Montano-Loza, Aldo and Ovchinsky, Nadia and Papadopoulou, Alexandra and Perito, Emily R and Sathya, Pushpa and Schwarz, Kathleen B and Shah, Uzma and Shteyer, Eyal and Soufi, Nisreen and Stevens, James Patrick and Taylor, Amy and Tessier, M Elizabeth and Valentino, Pamela and Woynarowski, Marek and Deneau, Mark and Pediatric PSC Consortium, Pediatric PSC Consortium},
title = {Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease ( PSC‐IBD ): A matched analysis from the Paediatric PSC Consortium},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {59},
number = {10},
pages = {1236--1247},
doi = {10.1111/apt.17936}
}
EUVIMED